Key terms
About MNKD
MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MNKD news
Mar 26
4:23pm ET
MannKind Corp Announces CFO Transition and New Compensation Plan
Mar 26
4:20pm ET
MannKind CFO Binder to retire, Christopher Prentiss named successor
Mar 11
6:09am ET
MannKind announces initial meal challenge data from INHALE-3 study
Mar 05
10:25am ET
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
Mar 05
4:55am ET
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
Mar 01
12:19pm ET
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
Mar 01
1:06am ET
MannKind’s Strong Q4 Financials and Therapeutic Portfolio Potential Merit a Buy Rating
Feb 28
8:55am ET
MannKind Corporation: Strong Growth and Clinical Advancements Prompt Buy Rating
Feb 28
8:35am ET
MannKind (MNKD) Receives a New Rating from Cantor Fitzgerald
Feb 28
7:19am ET
RBC Capital Sticks to Their Hold Rating for MannKind (MNKD)
Feb 27
4:04pm ET
MannKind reports Q4 EPS 0c, consensus 0c
Feb 27
3:19pm ET
MannKind options imply 10.8% move in share price post-earnings
Feb 15
6:17am ET
MannKind says INHALE-1 study now fully enrolled
Jan 05
8:47pm ET
MannKind (MNKD) Receives a Hold from RBC Capital
Jan 04
11:56pm ET
Strategic Deal Boosts MannKind’s Financial Prospects: A Buy Rating Justified
Jan 04
6:16am ET
MannKind Buy Rating Affirmed: Financial Strength and Market Potential Underpin Positive Outlook
Jan 02
6:07am ET
MannKind and Sagard Healthcare sign royalty purchase agreement for up to $200M
No recent news articles are available for MNKD
No recent press releases are available for MNKD
MNKD Financials
Key terms
Ad Feedback
MNKD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MNKD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range